Radiopharm Theranostics (ASX:RAD)
ASX announcement history & article coverage
Transparent by design.
Announcments by Radiopharm Theranostics (ASX:RAD) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification regarding unquoted securities - RAD
Change of Director's Interest Notices x 4
Notification of cessation of securities - RAD
Non-Compliance with Listing Rule 10.11
RAD Completes Meeting with US FDA for Development of RAD101
Radiopharm advances RAD101 toward Phase 3 after constructive FDA meeting
Notification of cessation of securities - RAD
Change of Director's Interest Notice (RC)
Appendix 4G and Corporate Governance Statement
Annual Report and Form 20-F
Radiopharm reports A$56.3m FY2026 loss and material going concern uncertainty as clinical programs advance
Change of Director's Interest Notices x 4
Notification regarding unquoted securities - RAD
RADOC New Class Options Range of Units and Top 20 Holders
Application for quotation of securities - RAD
Application for quotation of securities - RAD
Share purchase plan completed
RAD oral presentation at SNO26 on RAD101 Phase IIb data
Results of Meeting
RAD Announces Positive Data from RAD301 P1 Imaging Trial
Appendix 4E and Preliminary Final Report
Change of Director's Interest Notices x 4
RAD Doses First Patient in Second Cohort of BetaBart (RV-01)
Radiopharm Theranostics doses first patient in second cohort of Phase 1/2a RV-01 trial for B7-H3 solid tumors
Ceasing to be a substantial holder
RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
Radiopharm Theranostics Advances 177Lu-RAD202 Phase 1 Trial to Higher Dose Following Positive Safety Review
Change in substantial holding
RAD to meet with US FDA to align on RAD 101 Phase 3 Trial
Radiopharm Theranostics to meet FDA on Phase 3 trial design for RAD101 brain metastases imaging
Notice of Extraordinary General Meeting and Proxy Form
Share Purchase Plan - Now Open
Update - Proposed issue of securities - RAD
Application for quotation of securities - RAD
Quarterly Activities/Appendix 4C Cash Flow Report
Radiopharm Theranostics reports positive Phase 2b results for RAD 101 and plans Phase 3 trial; raises $12.5M post-quarter
Change in substantial holding
Target market determination (TMD)
Prospectus
Radiopharm Theranostics launches AUD 18.5 million equity raise with placement and share purchase plan
Notice Under Section 708A
Application for quotation of securities - RAD
Reinstatement to Quotation
Radiopharm Theranostics Limited reinstated to trading after capital raising announcement
Investor Presentation - Capital Raising
Radiopharm Theranostics launches A$18.5m capital raise following positive RAD101 Phase 2b results and advances clinical pipeline
Proposed issue of securities - RAD
Proposed issue of securities - RAD
RAD completes A$12.5 M placement and launches A$6 M SPP
Radiopharm Theranostics raises A$12.5 million institutional capital and launches A$6 million Share Purchase Plan
Suspension from Quotation
Radiopharm Theranostics requests voluntary suspension pending capital raising announcement
Trading Halt
RAD Achieves Partial Response in Phase 1 Trial of RAD204
Radiopharm Theranostics reports durable partial response and favorable safety in Phase 1 trial of RAD204
RAD Announces Positive Phase 2b Trial Results of RAD 101
Radiopharm Theranostics reports positive Phase 2b results for RAD101 brain metastases imaging, advancing to Phase 3 trial